Hospices Civils de Lyon, Université Lyon 1, Pierre-Bénite, France,
Int J Hematol. 2012 Nov;96(5):544-51. doi: 10.1007/s12185-012-1202-y. Epub 2012 Oct 30.
Follicular lymphoma is usually considered as incurable, but patient's outcome has been steadily improving over the last decade. The introduction of anti-CD20 monoclonal antibodies represented a major step. Treatment of patients should take into account accurate staging results, symptoms related to lymphoma, tumor burden, age and comorbidities. Several options are still available for patients with localized or asymptomatic low risk disease, and randomized studies should be developed for those patients. When a systemic therapy is needed, the combination of rituximab with a few of the available cytotoxic regimens clearly provides the best results. Rituximab maintenance appears to further improve the progression-free interval. Since most patients will likely survive for many years, the quality and duration of response as well as the short- and long-term side effects of the treatments should be carefully weighted during this prolonged therapeutic management.
滤泡性淋巴瘤通常被认为是不可治愈的，但在过去十年中，患者的预后一直在稳步改善。抗 CD20 单克隆抗体的引入是一个重大的进步。患者的治疗应考虑到准确的分期结果、与淋巴瘤相关的症状、肿瘤负荷、年龄和合并症。对于局部或无症状低危疾病的患者，仍有多种选择，应针对这些患者开展随机研究。当需要进行系统治疗时，利妥昔单抗联合几种可用的细胞毒性方案显然能提供最佳的疗效。利妥昔单抗维持治疗似乎进一步改善了无进展间期。由于大多数患者可能会存活多年，因此在这种长期的治疗管理中，应仔细权衡治疗的反应质量和持续时间以及短期和长期的副作用。
